BACKGROUND: In the past ~15  years, the identification of diagnostic and prognostic biomarkers from gene expression data has increased our understanding of @entity5 biology and has led to advances in the personalized treatment of many @entity5 . A diagnostic biomarker is indicative of @entity5 status such as @entity5 stage, while a prognostic biomarker is indicative of disease outcome. Despite these advances, however, there are no clinically approved biomarkers for the treatment of @entity150 , which is the fourth most common @entity5 in males in the United States and one of the most expensive @entity5 to treat. Although gene expression profiles of @entity150 @entity1 are publicly available, biomarker identification requires bioinformatics expertise that is not available to many research laboratories. DESCRIPTION: We collected gene expression data from 13 publicly available @entity1 cohorts (N   =   1454) and developed BC-BET, an online Bladder Cancer Biomarker Evaluation Tool for evaluating candidate diagnostic and prognostic gene expression biomarkers in @entity150 . A user simply selects a gene, and BC-BET evaluates the utility of that gene's expression as a diagnostic and prognostic biomarker. Specifically, BC-BET calculates how strongly a gene's expression is associated with @entity5 presence (distinguishing @entity5 from normal samples), @entity5 grade (distinguishing low- from high-grade @entity5 ), @entity5 stage (distinguishing non-muscle invasive from muscle invasive samples), and @entity1 outcome (e.g., disease-specific survival) across all @entity1 in each cohort. @entity1 with low-grade, non-muscle invasive @entity5 and @entity1 with high-grade, muscle invasive @entity5 are also analyzed separately in order to evaluate whether the biomarker of interest has prognostic value independent of grade and stage. CONCLUSION: Although @entity150 gene expression datasets are publicly available, their analysis is computationally intensive and requires bioinformatics expertise. BC-BET is an easy-to-use tool for rapidly evaluating @entity150 gene expression biomarkers across multiple @entity1 cohorts.

An online tool for evaluating diagnostic and prognostic gene expression biomarkers in XXXX .

@entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'cancer', 'tumors'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer']
@entity150 :: (MESH:D001749,Disease) :: ['bladder cancer']
